Literature DB >> 6100877

Long-term haemodynamic effects of enalapril (alone and in combination with hydrochlorothiazide) at rest and during exercise in essential hypertension.

P Lund-Johansen, P Omvik.   

Abstract

Nineteen patients (12 male and seven female) with essential hypertension (mean arterial pressure ranging from 113-162 mmHg) were studied at rest, supine and sitting, and during bicycle exercise (50, 100 and 150 W). Intra-arterial blood pressure and heart rate were recorded continuously. Cardiac output was measured by dye dilution (Cardiogreen). The patients were treated with enalapril 10-40 mg (mean 33 mg) once-daily; seven patients received in addition 25-50 mg hydrochlorothiazide daily. After 5-13 months (mean 10 months) patients were restudied. Blood pressure fell (P less than 0.001) in all - at rest sitting from 184/108 to 150/89 mmHg (-19%) and during 100 W bicycle exercise from 225/118 to 197/101 mmHg (-13%). Pretreatment total peripheral resistance index (TPRI) was markedly increased and fell at rest sitting from 4087 to 3514 dyn s/cm-5 m2 (-14%) (P less than 0.05). No significant change was seen in cardiac output, heart rate or stroke volume. Overall body weight and body fluid volume (isotope dilution technique) remained unchanged, but in the subgroup receiving enalapril + hydrochlorothiazide, blood volume fell by 12% (P less than 0.01). No side-effects were seen. In conclusion, enalapril monotherapy reduces blood pressure in two-thirds of patients with moderately severe essential hypertension at rest and during exercise, associated with a significant reduction in TPRI. One-third of patients require a diuretic in addition to enalapril. In this subgroup the reduction in TPRI was about twice the reduction seen during enalapril treatment alone, and there was a fall in blood volume.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6100877

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  6 in total

1.  Acute and long-term hemodynamic effects of tiapamil at rest and during exercise in essential hypertension.

Authors:  P Omvik; P Lund-Johansen
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

Review 2.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 3.  Drug treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 4.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

5.  Fosenopril, an angiotensin-converting enzyme inhibitor, and propranolol: comparative effects at rest and exercise on blood pressure, hormonal variables, and plasma potassium in essential hypertension.

Authors:  P A Sullivan; J Cervenka; D T O'Connor; M Dineen
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

Review 6.  Enalapril: a review of human pharmacology.

Authors:  H J Gomez; V J Cirillo; J D Irvin
Journal:  Drugs       Date:  1985       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.